Navigation Links
UofL physicians, Jewish Hospital first in Kentucky to offer new aortic valve replacement

Louisville, Ky. Some individuals with severe aortic stenosis also known as narrowing of the aortic valve in the heart who are not well enough to undergo open heart surgery have a new treatment option thanks to a new procedure now available in Kentucky from University of Louisville physicians at Jewish Hospital.

A team that included UofL cardiologists Michael Flaherty, M.D, Ph.D., and Naresh Solankhi, M.D., and UofL cardiothoracic surgeon Matthew Williams, M.D., performed the first transcatheter aortic-valve replacement (TAVR) procedure on a 47-year-old male patient on Dec. 21, 2011.

During the procedure a biological valve was inserted through a catheter and implanted within a diseased aortic valve. The procedure allows for valve replacement without traditional open-heart surgery and while the heart is beating, therefore avoiding cardiopulmonary bypass.

It is the only valve replacement option for patients with severe aortic stenosis who are not well enough to undergo traditional open-heart surgery, Flaherty said. Most patients will avoid any surgery in their chest.

"For patients who qualify, the TAVR procedure is often their last hope for treatment of their heart disease," said Flaherty, who is assistant professor of medicine, physiology and biophysics and director of research-interventional cardiology in UofL's Department of Medicine. "It's a unique procedure, and we are once again proud to be on the cutting edge of heart care in the region."

During the TAVR procedure, a cardiologist and cardiothoracic surgeon work together to implant the new heart valve, called the Edwards SAPIEN valve, which is made from cow tissue and developed by Edwards Lifesciences Corp.

The valve is inserted into the body through a small cut in the leg. Once delivered to the site of the patient's diseased valve, the Edwards SAPIEN valve is expanded with a balloon and immediately functions in place of the patient's valve.

Jewish Hospital is one of 29 sites in the United States where researchers are now studying the Edwards SAPIEN transcatheter aortic heart valve and the next-generation Edwards SAPIEN XT valve as part of an ongoing national clinical trial called the PARTNER II Trial. The Edwards SAPIEN valve studied in the first PARTNER Trial and used in Europe since 2007 recently received FDA approval for the treatment of inoperable patients in the United States. This is the first U.S. commercial approval for a transcatheter device enabling aortic valve replacement without the need for open-heart surgery.

"The availability of the TAVR procedure marks a major milestone in the treatment of valve-related heart disease," said Williams, who practices with University Cardiothoracic Surgical Associates and is assistant professor of thoracic and cardiovascular surgery in the Department of Surgery at UofL. "It gives us another tool to help take care of people. Older folks, who would prefer to avoid surgery if they can, will be the patients who will most often benefit."


Contact: Jill Scoggins
University of Louisville

Related biology news :

1. Analysis of Ashkenazi Jewish genomes reveals diversity, history
2. NIH awards National Jewish Health $31 million to lead study of infections associated with eczema
3. Gregory Downey, M.D., of National Jewish Health, honored for scientific accomplishments
4. National Jewish Health researchers discover how virulent bacteria
5. New genetic research indicates Jewish priesthood has multiple lineages
6. National Jewish Health researchers evaluating treatment to help emphysema sufferers breathe easier
7. Researchers at National Jewish Health evaluating a treatment
8. New disinfection technique could revolutionize hospital room cleaning
9. Brigham and Womens Hospital awarded $9.6 million to study whole genome sequencing
10. University Hospitals Seidman Cancer Center tests novel drug that makes brain tumors glow hot pink
11. University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging
Post Your Comments:
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology: